Fahey, C.C.; Clark-Garvey, S.; Porten, S.; Kamat, A.M.; Flaig, T.W.; Taylor, J.A.; Kim, W.Y.; Milowsky, M.I.
Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium. Curr. Oncol. 2025, 32, 278.
https://doi.org/10.3390/curroncol32050278
AMA Style
Fahey CC, Clark-Garvey S, Porten S, Kamat AM, Flaig TW, Taylor JA, Kim WY, Milowsky MI.
Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium. Current Oncology. 2025; 32(5):278.
https://doi.org/10.3390/curroncol32050278
Chicago/Turabian Style
Fahey, Catherine C., Sean Clark-Garvey, Sima Porten, Ashish M. Kamat, Thomas W. Flaig, John A. Taylor, William Y. Kim, and Matthew I. Milowsky.
2025. "Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium" Current Oncology 32, no. 5: 278.
https://doi.org/10.3390/curroncol32050278
APA Style
Fahey, C. C., Clark-Garvey, S., Porten, S., Kamat, A. M., Flaig, T. W., Taylor, J. A., Kim, W. Y., & Milowsky, M. I.
(2025). Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium. Current Oncology, 32(5), 278.
https://doi.org/10.3390/curroncol32050278
